Cardiac Muscle Regeneration Program

About IPS HEART

IPS HEART is a private, pre-clinical stage biotech founded in 2015 and based in San Diego, California. The company is pioneering iPSC-derived cellular therapies designed to regenerate functional muscle tissue for cardiac and skeletal muscle disorders, moving beyond symptomatic treatment to potential cures. It has garnered regulatory recognition from the FDA, including Orphan Drug and Rare Pediatric Disease Designations. The company is currently pre-revenue and is advancing a pipeline focused on two lead programs for heart failure and DMD.

Therapeutic Areas